Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3356173
Max Phase: Preclinical
Molecular Formula: C23H26F3N3O3
Molecular Weight: 449.47
Molecule Type: Small molecule
Associated Items:
ID: ALA3356173
Max Phase: Preclinical
Molecular Formula: C23H26F3N3O3
Molecular Weight: 449.47
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)CC(NC(=O)CCCCc1ccc2c(n1)NCCC2)c1cccc(C(F)(F)F)c1
Standard InChI: InChI=1S/C23H26F3N3O3/c24-23(25,26)17-7-3-5-16(13-17)19(14-21(31)32)29-20(30)9-2-1-8-18-11-10-15-6-4-12-27-22(15)28-18/h3,5,7,10-11,13,19H,1-2,4,6,8-9,12,14H2,(H,27,28)(H,29,30)(H,31,32)
Standard InChI Key: KRLSGXAAVBXUNS-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 449.47 | Molecular Weight (Monoisotopic): 449.1926 | AlogP: 4.50 | #Rotatable Bonds: 9 |
Polar Surface Area: 91.32 | Molecular Species: ACID | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.37 | CX Basic pKa: 7.52 | CX LogP: 1.80 | CX LogD: 1.57 |
Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.49 | Np Likeness Score: -0.54 |
1. Adams J, Anderson EC, Blackham EE, Chiu YW, Clarke T, Eccles N, Gill LA, Haye JJ, Haywood HT, Hoenig CR, Kausas M, Le J, Russell HL, Smedley C, Tipping WJ, Tongue T, Wood CC, Yeung J, Rowedder JE, Fray MJ, McInally T, Macdonald SJ.. (2014) Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents., 5 (11): [PMID:25408832] [10.1021/ml5002079] |
Source(1):